← vista completa

Publicado el 1 de septiembre de 2004 | http://doi.org/10.5867/medwave.2004.08.3496

Seroterapia monoclonal en cáncer: aplicaciones clínicas II

Monoclonal serum therapy in cancer: clinical applications (Part II)

Luis Villanueva O.

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Luis Villanueva O.

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Villanueva O. L. Monoclonal serum therapy in cancer: clinical applications (Part II). Medwave 2004;4(08):e3496 doi: 10.5867/medwave.2004.08.3496

Publicación 01/09/2004

Métricas del artículo

Artículo no tiene métricas.

Notas

Referencias

  1. Bast RC Jr, Kufe DW, Pollock RE, et al. Monoclonal Serotherapy. En: Holland-Frei Cancer Medicine. 5th edition. Hamilton (ON): BC Decker, 2000. | Link
  2. Skeel RT. Manual de quimioterapia del cáncer, 5ª edición. Philadelphia: Lippincott Williams & Wilkins, 2003.
  3. Tannock IF, Hill RP. Biological therapy of cáncer En:The basic science of Oncology. New York, NY: McGraw- Hill, 1998.
  4. Levy R. Karnofsky Lecture: immunotherapy of lymphoma. J Clin Oncol. 1999 Nov;17(11 Suppl):7-12. | PubMed
  5. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med. 1989 Oct 1;111(7):592-603. | PubMed
  6. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997 Sep 15;90(6):2188-95. | PubMed
  7. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. | PubMed
  8. Davis T, Levy R, White C. Rituximab: phase II (PII) retreatment (Rerx) study in patients (pts) with low-grade or follicular (LG/F) NHL [abstract]. Blood. 1998;92(Suppl):414a.
  9. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999 Jan;17(1):268-76. | PubMed
  10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42. | CrossRef | PubMed
  11. Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997 Jul;15(7):2667-72. | PubMed
  12. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554-61. | CrossRef | PubMed
  13. Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002 Aug 1;100(3):768-73. | CrossRef | PubMed
  14. Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol. 2003 May 1;21(9):1874-81. | CrossRef | PubMed
  15. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83. | PubMed
  16. Cobleigh MA, Vogle CL, Tripath D, et al: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol. 1998;17:97a(abstr 376).
  17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. | CrossRef | PubMed
  18. Hillan KJ. Rol de la expresión de VEGF en respuesta a Bevacizumab más Capecitabina en cáncer de mama metastásico. Reunión Anual de ASCO, 2003.
  19. Bolle M. Possible role of anti CA125 monoclonal antibody B43.13 (OvaRex) administration in long term survival of relapse ovarian cáncer patient. Proc Am Soc Cin Oncol. 2000;19(abstract 1876):476a.
  20. Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s. | PubMed
  21. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003 Jan 15;21(2):283-90. | CrossRef | PubMed
  22. Houghton AN. Melanoma. En: Biologic therapy of cáncer. Philadelphia: Lippincott, 1995:576.
  23. Richmuller G. University of Munich, Department of immunology and german 17-1 A Study group. Monoclonal antibody treatment of resected Dukes C colorectal cáncer. A prospective randomized trial. Proc Am Soc Clin Oncol. 1994;13:199.
  24. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003 Jul 31;349(5):427-34. | CrossRef | PubMed
  25. Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P, et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987 Jun 11;316(24):1499-505. | CrossRef | PubMed
  26. Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med. 1998 Aug;39(8 Suppl):21S-27S. | PubMed